Mucins in ovarian cancer diagnosis and therapy
Open Access
- 1 January 2009
- journal article
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 2 (1), 21
- https://doi.org/10.1186/1757-2215-2-21
Abstract
Ovarian cancer is the most lethal gynecologic malignancy and the five-year survival rate is only 35% after diagnosis. Epithelial ovarian cancer is a highly metastatic disease characterized by widespread peritoneal dissemination and ascites. The death incidences from ovarian cancer could be significantly lowered by developing new methods for the early diagnosis and treatment of this fatal disease. Several potential markers have been identified recently. However, mucins are the most promising markers for ovarian cancer diagnosis. Mucins are large extracellular, heavily glycosylated proteins and their aberrant expression has been implicated in the pathogenesis of a variety of cancers, including ovarian cancer. This review will summarize known facts about the pathological and molecular characteristics of ovarian cancer, the current status of ovarian cancer markers, as well as general information about mucins, the putative role of mucins in the progression of ovarian cancer and their potential use for the early diagnosis and treatment of this disease.Keywords
This publication has 96 references indexed in Scilit:
- Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)Immunology, 2007
- Multiple Hepatic Receptors Cooperate to Eliminate Secretory Mucins Aberrantly Entering the Bloodstream: Are Circulating Cancer Mucins the “Tip of the Iceberg”?Cancer Research, 2006
- MUC17, a Novel Membrane-Tethered MucinBiochemical and Biophysical Research Communications, 2002
- The Human DF3/MUC1 Carcinoma-Associated Antigen Signals Nuclear Localization of the Catenin p120ctnBiochemical and Biophysical Research Communications, 2001
- Multiple Transcripts of MUC3: Evidence for Two Genes, MUC3A and MUC3BBiochemical and Biophysical Research Communications, 2000
- The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markersEuropean Journal Of Cancer, 1999
- A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.Molecular Biology of the Cell, 1996
- Intramuscular immunisation withMUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cellsInternational Journal of Cancer, 1996
- Subunit structure of porcine submaxillary mucinBiochemistry, 1989
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983